Download PDFPDF
What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Anti-TNFalpha treatment decreases procoagulant activity in patients with rheumatoid arthritis
    • Piotr Gluszko, Rheumatologist
    • Other Contributors:
      • Tomasz Löwenhoff, Teresa Iwaniec, Anetta Undas, Barbara Gajkowska, Antoni Skura

    Dear Editor,

    In their interesting review, Dixon W.G. and Symmons D.P.M (1) discuss the role of TNF alpha and other factors, which may contribute to the increased cardiovascular morbidity in patients with rheumatoid arthritis (RA). The Authors support a hypothesis that TNF alpha blockade may reduce development of atherosclerosis in RA.

    There is also a growing body of evidence that TNF alpha and other inflammatory...

    Show More
    Conflict of Interest:
    None declared.